NICE changes mind on Amgen’s cholesterol drug
February 8, 2016Manufacturing and Production, Sales and Marketing Amgen, NICE, Repatha
NICE has changed its mind on Amgen’s cholesterol-busting drug Repatha (evolocumab), and decided to recommend approval of the treatment in …
Merck partners with Ugandan Health Ministry to tackle cancer awareness
February 8, 2016Manufacturing and Production, Medical Communications Africa, Cancer, Merck
Germany’s Merck celebrated World Cancer Day by collaborating with the Uganda Ministry of Health to raise awareness about early detection …
NICE rejects cholesterol drug Praluent in draft guidance
February 8, 2016Research and Development, Sales and Marketing NICE, Regeneron, Sanofi, cholesterol
NICE has published draft guidance not recommending Sanofi/Regeneron’s Praluent (alirocumab) as an option for people with high cholesterol (primary hypercholesterolaemia …
UK Health Secretary sets out £4.2 billion ‘digital NHS’ vision
February 8, 2016Medical Communications, Sales and Marketing Jeremy Hunt, NHS
UK Health Secretary Jeremy Hunt has announced a £4.2 billion investment in the National Health Service (NHS) which will help …
FDA to decide on Shire blockbuster hopeful
February 8, 2016Manufacturing and Production, Research and Development, Sales and Marketing Shire, dry eye disease, lifitegrast
The FDA has accepted Shire’s new drug application (NDA) for its dry eye disease drug lifitegrast, putting the treatment on …
UK lung cancer patients get early access to breakthrough BMS drug
February 5, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, MHRA, NICE, eams, opdivo
UK lung cancer patients are to get access to Bristol Myers-Squibb’s Opdivo (nivolumab) through the Early Access to Medicines Scheme …
Big pharma answers tough questions at US drug pricing hearing
February 5, 2016Medical Communications Drug pricing, FDA, Martin Shkreli, Senate, Turing Pharmaceuticals, US, Valeant, congress
Pharmaceutical industry executives came under intense scrutiny at a Congressional hearing in the US as the debate over the spiralling …
Parliamentary committee says CDF must make better use of taxpayer money
February 5, 2016Medical Communications Cancer Drugs Fund, Public Accounts Committee
The Cancer Drugs Fund, set up to improve patients’ access to cancer drugs, has not been managed effectively, a UK …
Lundbeck gets go-ahead for US and EU licence expansions
February 4, 2016Medical Communications, Sales and Marketing Abilify, EMA, FDA, Lundbeck, Otsuka, Takeda, aripiprazole, brintellix, vortioxetine
Lundbeck has earned two recommendations from regulatory committees of the FDA and the EMA, which both recommended the company’s drugs …
Investigation questions Xarelto trial data accuracy
February 4, 2016Medical Communications BMJ, Bayer, INR, Johnson & Johnson, New England Journal of Medicine, Rocket-AF, Xarelto, blood clotting, rivaroxaban
The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been undermined by unreliable results from …
Human Longevity makes three oncology appointments
February 4, 2016Research and Development human longevity
Human Longevity, the genomics-based, technology company, has appointed ‘several key people’ for its oncology genomics program.Dr Kenneth Bloom will join …
AZ warns of patent losses as revenues fall
February 4, 2016Medical Communications, Sales and Marketing AstraZeneca, Crestor, Zurampic
AstraZeneca announced full-year revenues down 7% to $24.7 billion, and Q4 sales down 5% to $6.4 billion, as the London-based …
Cancer – dealing with the greatest health challenge of our time
February 4, 2016Manufacturing and Production, Research and Development Cancer, IFPMA, R&D, World Cancer Day, collaboration, partnership
Cancer is one of the greatest health challenges of our time, and a leading cause of death in every corner …
AstraZeneca’s Tagrisso gets EU lung cancer sign-off
February 4, 2016Sales and Marketing AstraZeneca, European Commission, NSCLC, Tagrisso, non-small cell lung cancer, osimertinib
The European Commission (EC) has granted conditional marketing authorisation to AstraZeneca’s Tagrisso to treat locally advanced or metastatic non-small cell …
Revenues down at MSD
February 4, 2016Sales and Marketing MSD, financial performance, profits, revenue, sales
MSD (Merck, Sharpe and Dohme) reported a mixed bag of financial figures today, as the company announced full-year 2015 revenues …
Emerging markets top global R&D spending league
February 4, 2016Research and Development GDP, OECD, R&D spending, investment
Data from the Organisation for Economic Co-operation and Development (OECD) shows Korea and Israel are investing much more in research …
Revealed: analysts predict seven highest-earning pharma blockbusters
February 4, 2016Sales and Marketing Gilead, OCA, Thomson Reuters, blockbusters, sales
Seven new drugs currently in development will enter the market this year – and earn sales of more than $1 …
Rodger Currie to lead advocacy at US pharma trade body
February 3, 2016Medical Communications PhRMA, Pharmaceutical Research and Manufacturers of America
Rodger Currie has joined the Pharmaceutical Research and Manufacturers of America (PhRMA) association as executive vice president for advocacy.He will lead federal, …
London launches new cancer drug development hub
February 3, 2016Research and Development
Research charities, hospitals, and London boroughs have combined to launch a new global hub for cancer research and treatment in …
GSK and Adaptimmune expand R&D collaboration
February 3, 2016Research and Development Adaptimmune, GSK, T-cell therapy, immunotherapy, liposarcoma, rare cancer, sarcoma
Adaptimmune Therapeutics and GlaxoSmithKline have expanded the terms of their strategic collaboration agreement, to run clinical trials of Adaptimmune’s potential …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
